Relay Therapeutics, Inc.
RLAY · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
Business Summary
4 Item 1A. Risk Factors Item 1B. Unresolved Staff Comments 74 Item 1C. Cybersecurity 75 Item 2. Properties 75 Item 3. Legal Proceedings 75 Item 4. Mine Safety Disclosures 76 PART II Item 5. Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 77 Item 6. [Reserved] 78 Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations 79 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 90 Item 8. Fi...
Next Earnings
Q2 FY2026 — expected 2026-08-09
Key Facts from Earnings Calls
| Type | Subject | Detail | Quarter |
|---|
| topic_mention | RLAY | discussed_in_filing Cybersecurity | |
| topic_mention | RLAY | discussed_in_filing Cybersecurity | |
| topic_mention | RLAY | discussed_in_filing Cybersecurity | |
| topic_mention | RLAY | discussed_in_filing Cybersecurity | |
Annual Reports (10-K)
| Filed | Period | Accession | Source | Full Text |
|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-076739 | EDGAR | 102K words |
| 2025-02-26 | 2024-12-31 | 0000950170-25-027756 | EDGAR | — |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018797 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0000950170-23-004123 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0000950170-22-001978 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001564590-21-015518 | EDGAR | — |
Quarterly Reports (10-Q)
| Filed | Period | Accession | Source | Full Text |
|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269601 | EDGAR | 63K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105054 | EDGAR | — |
| 2025-05-05 | 2025-03-31 | 0000950170-25-063553 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122332 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0000950170-24-091837 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0000950170-24-052135 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0000950170-23-058237 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039874 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017894 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021892 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014809 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0000950170-22-007873 | EDGAR | — |
Recent Current Reports (8-K)
| Filed | Accession | Source | Full Text |
|---|
| 2026-03-16 | 0001193125-26-107312 | EDGAR | 2K words |
| 2026-03-11 | 0001193125-26-102178 | EDGAR | — |
| 2026-02-26 | 0001193125-26-076617 | EDGAR | — |
| 2026-02-03 | 0001193125-26-034422 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269536 | EDGAR | — |
| 2025-08-07 | 0000950170-25-105022 | EDGAR | — |
| 2025-06-11 | 0001193125-25-139146 | EDGAR | — |
| 2025-06-06 | 0001193125-25-137162 | EDGAR | — |
| 2025-06-04 | 0001193125-25-134908 | EDGAR | — |
| 2025-05-05 | 0000950170-25-063539 | EDGAR | — |
97 total filings indexed. 69 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
Sector Peers
Company Identity
| CIK | 0001812364 |
| Ticker | RLAY |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
Get More Data
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile
Stock Quote
AI Readiness Report
Origin Provenance
page leaf: 3f2651e988a55e692562ad159a6cffeedd91fe29c4d916f7fd9b7aaff33e7c71
parent: 1a78b996c31cfc657dcc99666bf1bd582c93084c35034a47975ab5cb3fa04172
content hash: 8d01d98a2770fb9feaa2988a9cc653f22eb14ddf61450d6ca31ac95a23cf0cf4
signed: 2026-04-13T04:47:12.524Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf